Literature DB >> 11106250

Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro.

F J Kelly1, C R Miller, D J Buchsbaum, J Gomez-Navarro, M N Barnes, R D Alvarez, D T Curiel.   

Abstract

Efficient gene transfer by recombinant adenovirus (Ad) vectors depends on expression of CAR and alpha(v) integrin on target cells. Because Ad may also infect nearby nontarget cells expressing these receptors, such as peritoneal mesothelial cells after i.p. injection, we hypothesized that targeting Ad gene delivery to a receptor overexpressed on most ovarian carcinoma cells, such as TAG-72, would enhance the selectivity of Ad gene transfer when used in this context. A monoclonal antibody that has been investigated clinically for immunotherapy and immunodetection of ovarian carcinomas, namely CC49, was used to construct a bispecific conjugate with the Fab fragment of a neutralizing anti-knob mAb to target Ad binding via TAG-72. This conjugate facilitated TAG-72-specific, CAR-independent Ad reporter gene transfer to both ovarian cancer cell lines and primary ovarian cancer cells cultured from malignant ascites fluid. Fab-CC49 was very selective for tumor cells, augmenting Ad gene transfer to primary ovarian cancer cells 2- to 28-fold relative to untargeted Ad, while also decreasing gene transfer to autologous cultured mesothelial cells 4- to 9-fold. These data suggest that targeting Ad via TAG-72 may improve the selectivity of Ad gene transfer for ovarian tumors 8- to 252-fold on i.p. vector injection. These results also define the requirements for a candidate target receptor in the rational design of a targeted Ad vector for ultimate clinical utility, one that selectively infects tumor cells and spares normal cells on i.p. injection. Such a vector may increase gene transfer and decrease the toxicity of Ad vectors, which would improve the therapeutic index of cytotoxic gene therapy for ovarian cancer in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106250

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model.

Authors:  Lena J Gamble; Hideyo Ugai; Minghui Wang; Anton V Borovjagin; Qiana L Matthews
Journal:  J Mol Biochem       Date:  2012-02-15

Review 2.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

3.  Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).

Authors:  Lena J Gamble; Anton V Borovjagin; Qiana L Matthews
Journal:  Exp Ther Med       Date:  2010-03       Impact factor: 2.447

4.  Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells.

Authors:  J L Dembinski; E L Spaeth; J Fueyo; C Gomez-Manzano; M Studeny; M Andreeff; F C Marini
Journal:  Cancer Gene Ther       Date:  2009-10-30       Impact factor: 5.987

5.  Oncolytic virotherapy for ovarian cancer.

Authors:  Shoudong Li; Jessica Tong; Masmudur M Rahman; Trevor G Shepherd; Grant McFadden
Journal:  Oncolytic Virother       Date:  2012-08

Review 6.  Chapter two--Adenovirus strategies for tissue-specific targeting.

Authors:  Matthew S Beatty; David T Curiel
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

7.  A preliminary study on the expression of tumor-associated glycoprotein-72 in human gliomas.

Authors:  Dongchun Wang; Yan Zhang; Xiaoli Li; Jianzhong Cui; Shuo Wang
Journal:  Med Oncol       Date:  2011-07-23       Impact factor: 3.064

8.  A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway.

Authors:  Yuko Tsuruta; Larisa Pereboeva; Joel N Glasgow; Daniel T Rein; Yosuke Kawakami; Ronald D Alvarez; Rodney P Rocconi; Gene P Siegal; Paul Dent; Paul B Fisher; David T Curiel
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

9.  p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.

Authors:  Magdalena B Flak; Claire M Connell; Claude Chelala; Kyra Archibald; Michael A Salako; Katrina J Pirlo; Michelle Lockley; Sally P Wheatley; Frances R Balkwill; Iain A McNeish
Journal:  Mol Cancer       Date:  2010-07-03       Impact factor: 27.401

10.  Adenoviral vector-based strategies for cancer therapy.

Authors:  Anurag Sharma; Manish Tandon; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Drug ther       Date:  2009-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.